@article{oai:repo.qst.go.jp:00080033,
 author = {Takeuchi, Hiroki and Imamura, Keiko and Ji, Bin and Tsukita, Kayoko and Enami, Takako and Takao, Keizo and Miyakawa, Tsuyoshi and Hasegawa, Masato and Sahara, Naruhiko and Iwata, Nobuhisa and Inoue, Makoto and Hara, Hideo and Tabira, Takeshi and Ono, Maiko and Trojanowski, John and Lee, Virginia and Takahashi, Ryosuke and Suhara, Tetsuya and Higuchi, Makoto and Inoue, Haruhisa and Ji, Bin and Sahara, Naruhiko and Ono, Maiko and Suhara, Tetsuya and Higuchi, Makoto and Inoue, Haruhisa},
 issue = {28},
 journal = {npj Vaccines},
 month = {Mar},
 note = {Pathological aggregates of tau proteins accumulate in the brains of neurodegenerative tauopathies including Alzheimer’s disease and frontotemporal lobar degeneration (FTLD-tau). Although immunotherapies of these disorders against tau are emerging, it is unknown whether nasal delivery, which offers many benefits over traditional approaches to vaccine administration, is effective or not for tauopathy. Here, we developed vaccination against a secreted form of pathological tau of FTLD-tau using a Sendai virus (SeV) vector infectious to host nasal mucosa, a key part of the immune system. Tau vaccines given as nasal drops induced tissue tau-immunoreactive antibody production and ameliorated cognitive impairment in FTLD-tau model mice. In vivo imaging and postmortem neuropathological assays demonstrated the suppression of phosphorylated tau accumulation, neurotoxic gliosis and neuronal loss in the hippocampus of immunized mice. These findings suggest that nasal vaccine delivery may provide a therapeutic opportunity for a broad range of populations with human tauopathy.},
 title = {Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice},
 volume = {5},
 year = {2020}
}